Compare NRO & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRO | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 197.2M |
| IPO Year | 2003 | N/A |
| Metric | NRO | WHWK |
|---|---|---|
| Price | $3.05 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 295.7K | 182.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.74 | $1.57 |
| 52 Week High | $3.37 | $4.40 |
| Indicator | NRO | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 50.38 |
| Support Level | $2.98 | $3.77 |
| Resistance Level | $3.10 | $4.38 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 59.09 | 40.91 |
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.